New blood test that detects cancer by measuring glycosidase enzyme activity with volatile ethanol probes.
Official title: Evaluation of a New Method for Detecting Cancer Pathologies by Measuring the Activity of Different Glycosidases in Plasma in Patients With Localized Cancer - Pilot Study: B-GLUCANCER2
Run by Poitiers University Hospital · NCT07236177 · Data updated 2026-11-12
This pilot will test whether a blood test using volatile probes that release ethanol can detect localized breast, lung, and pancreatic cancers in patients scheduled for surgery.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 220 (estimated) |
| Sponsor | Poitiers University Hospital Academic / other |
| Locations | 1 site (Poitiers) |
| Status | Recruiting |
| Started | February 3, 2026 |
| Main results expected | February 3, 2028 |
| Study ends | March 3, 2028 |
| Registry record updated | February 5, 2026 |
| Trial ID | NCT07236177 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal participants are adults with confirmed, untreated localized breast, lung, or pancreatic cancer who are scheduled for initial surgical treatment, as well as healthy adult volunteers for the control group.
✕Probably not a fit
Patients with metastatic disease, those already receiving cancer therapy, minors, pregnant or breastfeeding women, and people under legal protection are excluded and unlikely to receive benefit from this pilot.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will add a panel of volatile organic compound probes to small plasma samples; each probe is designed to be cleaved by a specific glycosidase and release a labeled ethanol isotope that can be detected in the gas phase. The trial enrolls three patient groups with confirmed, untreated localized breast, lung, or pancreatic cancer and a larger control group without cancer. Cancer patients provide two 5 mL plasma samples (one before and one after surgery) while healthy volunteers give a single 5 mL sample. The primary objective is to compare glycosidase activity levels measured in plasma between the cancer groups and controls to explore diagnostic and prognostic signals.
Why it matters
Potential benefit: If successful, this could become a simple, non‑invasive blood test to help detect and monitor localized breast, lung, and pancreatic cancers earlier or guide surgical decision making.
How similar studies have gone: This precise technique—using exogenous volatile probes that liberate ethanol isotopes to report glycosidase activity—is novel and largely untested in humans, although other enzyme‑based blood biomarkers have been explored.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Group 1: 40 patients with definitively diagnosed, untreated, localized solid breast cancer referred for initial surgical treatment. Group 2: 40 patients with definitively diagnosed, untreated, localized solid lung cancer referred for initial surgical treatment. Group 3: 40 patients with definitively diagnosed, untreated, localized solid pancreatic cancer referred for initial surgical treatment. Group 4: 100 control patients with no cancer diagnosis or history of solid or hematological cancer. Exclusion Criteria: * Refusal to participate in the research. * Patients benefiting from enhanced protection, namely: minors, pregnant/breastfeeding women, persons deprived of their liberty by a judicial or administrative decision, persons staying in a social care facility, adults under legal protection Specific criteria for groups 1, 2, and 3: * Cancer patients undergoing oncological treatment. * Cancer not proven by anatomopathological examination.
Where it's running
-
C.H.U. Poitiers
Poitiers, France Recruiting
Study contacts
- Study coordinator: Sheik Emambux, MD PhD
- Email: sheik.emambux@chu-poitiers.mssante.fr
- Phone: +33549444279
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
68Ga-SorB PET/CT imaging for solid tumors
This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.
-
CAIX-targeted 18F-T2 PET/CT imaging in solid tumors
This study tests a CAIX-specific radioactive tracer to see if PET/CT can help visualize solid tumors and checks safety and radiation exposure in adults with certain cancers.
-
LRRC15-targeted PET imaging for more precise diagnosis and staging of pancreatic, breast, lung, sarcoma and head-and-neck cancers
This project tests whether an LRRC15-targeted PET scan can better detect and stage LRRC15-expressing cancers and measures how the tracer behaves in healthy adults.
-
Adherence to a Remote Physical Activity Program on a Smartwatch and its Effect on Fatigue After Adjuvant Chemotherapy
This study tests whether sticking with an adapted physical activity program tracked on a smartwatch can reduce fatigue in adults who have finished adjuvant chemotherapy for certain cancers.
-
Digital app to support oncologist‑initiated genetic testing
This project tests a digital app (GA‑Mainstream) to help oncologists offer germline genetic testing to adults with breast, prostate, colon, or other GI cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.